Facebook
Twitter
LinkedIn
ForwardControlled Substances, Telemedicine, and DEA 2023: Navigating the Regulatory Gauntlet
Main street practitioners face typical business and workflow challenges as they try to incorporate telemedicine into daily medical practice. These challenges increase when controlled substances are part of a patient's treatment plan. This course will address the current legal-regulatory landscape - federal and state - involving controlled substance prescribing and telemedicine. Attendees will actively work through several case examples to evaluate the prescriber's conduct and to illustrate critical documentation requirements for demonstrating proper use of telemedicine if controlled substances are prescribed through telemedicine visits. Additional Reading Materials
Jennifer Bolen, JD
Founder/Owner
The J. Bolen Group, LLC
Lenoir City, TN
Jennifer Bolen, JD, is the founder and owner of the J Bolen Group, LLC d/b/a the Legal Side of Pain. She is an actively licensed attorney and a former federal prosecutor. Ms. Bolen has nearly 20 years of experience in legal, regulatory, and compliance matters impacting pain medicine, addiction treatment, and clinical toxicology. Ms. Bolen frequently serves as a subject matter expert to attorneys and law firms nationwide on legal matters impacting physicians, nurse practitioners, and clinical laboratory owners. Ms. Bolen proudly serves PainWeek and its attendees and looks forward to engaging attendees in discussions designed to guide daily practice and proactive business and practice compliance measures.